MRNA news · MRNA stock

Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says

Yahoo Finance · Sep 2, 2026 · Moderna Inc (MRNA)

Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitini

Original at Yahoo Finance

Not investment advice. Cached headline, not a full reprint.